Completed PHASE3 INTERVENTIONAL 2-arm NCT03984214

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Dronabinol in the Improvement of ChemOthErapy-induced and Tumor-Related Symptoms in Patients With Locally Advanced or Metastatic Pancreatic Cancer During First-line Chemotherapy (DIsCOvER)

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Conditions Chemotherapy-induced Nausea and Vomiting Pancreatic Cancer Metastatic Pancreatic Cancer Non-resectable

Interventions Dronabinol in Oral Dosage Form Placebo in Oral Dosage Form

Updated 16 times since 2019 Last updated: Apr 9, 2025 Started: Dec 16, 2019 Primary completion: Sep 25, 2024 Completion: Sep 25, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chemotherapy-induced Nausea and Vomiting and Pancreatic Cancer Metastatic, this trial is completed. The trial is conducted by Arbeitsgemeinschaft medikamentoese Tumortherapie and has accumulated 16 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

16 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
May 2025 — Sep 2025 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Sep 2024 — May 2025 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
May 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting

▶ Show 11 earlier versions

Dec 2023 — May 2024 [monthly]

Recruiting PHASE3
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Feb 2022 — Oct 2023 [monthly]

Recruiting PHASE3
Sep 2021 — Feb 2022 [monthly]

Recruiting PHASE3
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Oct 2020 — Dec 2020 [monthly]

Recruiting PHASE3
May 2020 — Oct 2020 [monthly]

Recruiting PHASE3
Jan 2020 — May 2020 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Aug 2019 — Jan 2020 [monthly]

Not Yet Recruiting PHASE3
Jul 2019 — Aug 2019 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arbeitsgemeinschaft medikamentoese Tumortherapie
Bionorica SE
Medical University of Graz
Unidata Geodesign

Data source: Arbeitsgemeinschaft medikamentoese Tumortherapie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Göttingen, Germany , Klagenfurt, Austria , Leoben, Austria , München, Germany , Salzburg, Austria , Sankt Veit an der Glan, Austria , Steyr, Austria , Stuttgart, Germany , Vienna, Austria , Wels, Austria and 1 more location